Karyopharm Therapeutics Inc. (KPTI) Reaches $14.37 52-Week High; Energous (WATT) Sellers Decreased By 4.49% Their Shorts

February 15, 2018 - By Marie Mckinney

The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) hit a new 52-week high and has $14.94 target or 4.00% above today’s $14.37 share price. The 6 months bullish chart indicates low risk for the $711.79M company. The 1-year high was reported on Feb, 15 by Barchart.com. If the $14.94 price target is reached, the company will be worth $28.47M more. The stock decreased 0.76% or $0.11 during the last trading session, reaching $14.37. About 179,584 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 15, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Energous Corporation (NASDAQ:WATT) had a decrease of 4.49% in short interest. WATT’s SI was 5.05 million shares in February as released by FINRA. Its down 4.49% from 5.29M shares previously. With 247,600 avg volume, 20 days are for Energous Corporation (NASDAQ:WATT)’s short sellers to cover WATT’s short positions. The SI to Energous Corporation’s float is 31.81%. The stock increased 0.30% or $0.06 during the last trading session, reaching $20.22. About 1.01M shares traded. Energous Corporation (NASDAQ:WATT) has risen 57.63% since February 15, 2017 and is uptrending. It has outperformed by 40.93% the S&P500.

Since August 29, 2017, it had 0 buys, and 17 insider sales for $1.27 million activity. Shares for $100,769 were sold by Shacham Sharon. 10,000 shares valued at $100,882 were sold by Kauffman Michael on Thursday, January 18. Primiano Christopher Brett sold $19,500 worth of stock or 1,500 shares. Shares for $1,298 were sold by Mirza Mansoor Raza.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on March, 15. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.65 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -10.77% EPS growth.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $711.79 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.36’s average target is 69.52% above currents $14.37 stock price. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 11. The firm has “Overweight” rating by JP Morgan given on Wednesday, September 2. The rating was initiated by Jefferies on Wednesday, September 9 with “Buy”. The rating was downgraded by Bank of America on Tuesday, March 15 to “Underperform”. On Tuesday, August 8 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating by Jefferies given on Thursday, October 12. The firm earned “Buy” rating on Friday, June 23 by Cantor Fitzgerald. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. The company was maintained on Wednesday, August 12 by MLV.

Investors sentiment increased to 2.5 in 2017 Q3. Its up 0.94, from 1.56 in 2017Q2. It is positive, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. Barclays Public Limited Company has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Thomas J Herzfeld Advsr holds 0.02% or 4,868 shares. Citadel Advisors Limited Liability Corporation has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). First Personal Financial Svcs accumulated 0% or 1,187 shares. State Of Wisconsin Investment Board reported 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Tcw Group owns 40,648 shares. Credit Suisse Ag has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 32,039 shares. Manufacturers Life Insur The accumulated 26,084 shares or 0% of the stock. Tekla Cap Mgmt Ltd Liability Corporation holds 0.3% or 756,679 shares in its portfolio. Virtu Financial Limited Com reported 18,293 shares or 0% of all its holdings. Northern Corp reported 416,232 shares. Moreover, Great West Life Assurance Can has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Mutual Of America Cap Management owns 154,449 shares or 0.03% of their US portfolio. Automobile Association reported 0% stake. Pennsylvania-based Vanguard Group Inc Inc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Among 3 analysts covering Energous Corp (NASDAQ:WATT), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Energous Corp had 9 analyst reports since August 14, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, August 14 by Zacks. The firm earned “Perform” rating on Tuesday, January 24 by Oppenheimer. The rating was maintained by Oppenheimer with “Hold” on Thursday, August 10. The stock of Energous Corporation (NASDAQ:WATT) has “Buy” rating given on Monday, December 7 by Ladenburg Thalmann. Oppenheimer maintained Energous Corporation (NASDAQ:WATT) on Friday, January 5 with “Hold” rating. The stock of Energous Corporation (NASDAQ:WATT) has “Buy” rating given on Monday, August 7 by Roth Capital. Oppenheimer maintained it with “Buy” rating and $13 target in Monday, September 21 report. The company was maintained on Saturday, August 22 by Oppenheimer. On Thursday, December 28 the stock rating was maintained by Roth Capital with “Buy”.

Since August 21, 2017, it had 0 insider purchases, and 10 selling transactions for $1.31 million activity. Another trade for 15,000 shares valued at $188,316 was sold by Johnston Cesar. Leabman Michael Aaron sold 10,515 shares worth $97,933. Sahejpal Neeraj had sold 9,867 shares worth $123,651 on Monday, September 11. Sereda Brian J also sold $44,240 worth of Energous Corporation (NASDAQ:WATT) shares. Gaulding John sold $268,714 worth of stock.

Investors sentiment increased to 1.42 in Q3 2017. Its up 0.17, from 1.25 in 2017Q2. It improved, as 10 investors sold Energous Corporation shares while 14 reduced holdings. 17 funds opened positions while 17 raised stakes. 8.61 million shares or 9.20% more from 7.88 million shares in 2017Q2 were reported. Herald Investment Management Ltd has invested 0.41% in Energous Corporation (NASDAQ:WATT). Reilly Fincl Advsrs Lc invested 0% in Energous Corporation (NASDAQ:WATT). California State Teachers Retirement System stated it has 0% of its portfolio in Energous Corporation (NASDAQ:WATT). Glenmede Trust Na has invested 0% in Energous Corporation (NASDAQ:WATT). Nationwide Fund reported 10,741 shares or 0% of all its holdings. Parkside Retail Bank And Tru has 1,750 shares. Next Inc has invested 0% of its portfolio in Energous Corporation (NASDAQ:WATT). Citadel Advsrs Lc accumulated 94,722 shares or 0% of the stock. State Street reported 0% stake. Alliancebernstein L P has invested 0% of its portfolio in Energous Corporation (NASDAQ:WATT). Frontier Investment invested 0.02% of its portfolio in Energous Corporation (NASDAQ:WATT). Ls Advsrs Limited Liability invested 0% of its portfolio in Energous Corporation (NASDAQ:WATT). Tiaa Cref Mngmt Limited Company owns 48,828 shares. Ascend Capital Lc has 1.62M shares for 0.77% of their portfolio. Schwab Charles Investment Mgmt reported 0% in Energous Corporation (NASDAQ:WATT).

Energous Corporation engages in the development of a wire-free charging system. The company has market cap of $449.17 million. The companyÂ’s technology could enable wire-free charging solutions for contact charging, as well as at a distance charging. It currently has negative earnings. It develops WattUp, a wire-free charging technology that charges electronic devices by surrounding them with a contained three dimensional radio frequency energy pocket.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>